Allan Lawrie

11.2k total citations
106 papers, 4.4k citations indexed

About

Allan Lawrie is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Allan Lawrie has authored 106 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 30 papers in Molecular Biology and 24 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Allan Lawrie's work include Pulmonary Hypertension Research and Treatments (74 papers), Cardiovascular Function and Risk Factors (13 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers). Allan Lawrie is often cited by papers focused on Pulmonary Hypertension Research and Treatments (74 papers), Cardiovascular Function and Risk Factors (13 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers). Allan Lawrie collaborates with scholars based in United Kingdom, United States and Switzerland. Allan Lawrie's co-authors include Sheila Francis, A. A. Roger Thompson, David G. Kiely, Robin Condliffe, Axel F. Brisken, D.C. Cumberland, Ian Sabroe, David C. Crossman, Alexander Rothman and Sébastien Bonnet and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Allan Lawrie

98 papers receiving 4.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Allan Lawrie United Kingdom	40	2.2k	1.3k	1.1k	549	541	106	4.4k
Jeffrey A. Jones United States	39	1.4k 0.6×	1.3k 1.0×	782 0.7×	411 0.7×	109 0.2×	130	4.4k
Keiichi Ito Japan	34	943 0.4×	1.3k 1.0×	887 0.8×	511 0.9×	186 0.3×	349	4.3k
Jaroslav Pelisek Germany	40	1.5k 0.7×	1.9k 1.4×	902 0.8×	575 1.0×	372 0.7×	127	5.3k
Henri H. Versteeg Netherlands	37	755 0.3×	1.7k 1.3×	1.0k 0.9×	706 1.3×	237 0.4×	129	7.1k
Carl Atkinson United States	38	1.6k 0.7×	1.1k 0.8×	531 0.5×	404 0.7×	176 0.3×	141	4.9k
Kewal Asosingh United States	43	1.4k 0.6×	1.9k 1.4×	411 0.4×	578 1.1×	98 0.2×	118	4.4k
Caroline Cheng Netherlands	35	710 0.3×	1.3k 1.0×	1.1k 1.0×	450 0.8×	275 0.5×	92	4.1k
Claudia Goettsch Germany	38	578 0.3×	2.0k 1.5×	700 0.6×	634 1.2×	154 0.3×	77	4.2k
Carla Di Loreto Italy	38	675 0.3×	3.0k 2.3×	1.1k 1.0×	1.1k 2.0×	244 0.5×	150	6.4k
Alberto Smith United Kingdom	40	862 0.4×	1.1k 0.9×	597 0.5×	522 1.0×	148 0.3×	96	4.2k

Countries citing papers authored by Allan Lawrie

Since Specialization

Citations

This map shows the geographic impact of Allan Lawrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Lawrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Lawrie more than expected).

Fields of papers citing papers by Allan Lawrie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan Lawrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Lawrie. The network helps show where Allan Lawrie may publish in the future.

Co-authorship network of co-authors of Allan Lawrie

This figure shows the co-authorship network connecting the top 25 collaborators of Allan Lawrie. A scholar is included among the top collaborators of Allan Lawrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Lawrie. Allan Lawrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boucly, Athénaïs, Shanshan Song, Dennis Wang, et al.. (2025). Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome. American Journal of Respiratory and Critical Care Medicine. 211(8). 1492–1503. 1 indexed citations

Rhodes, Christopher J., Lihan Zhou, Lihan Zhou, et al.. (2025). Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension. Circulation Genomic and Precision Medicine. 18(3). e004862–e004862. 1 indexed citations

Julian, Thomas, A. A. Roger Thompson, Christopher J. Rhodes, et al.. (2024). Mendelian Randomization Study With Clinical Follow‐Up Links Metabolites to Risk and Severity of Pulmonary Arterial Hypertension. Journal of the American Heart Association. 13(6). e032256–e032256. 6 indexed citations

Howard, Luke, Olivier Sitbon, Dennis Wang, et al.. (2024). Therapeutic Implications of Plasma Proteome Clusters in Pulmonary Hypertension. A7127–A7127.

Kiely, David G., Neil Hamilton, Fernando G. Exposto, et al.. (2024). Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service. BMJ Open. 14(1). e080068–e080068. 3 indexed citations

Lawrie, Allan, Kelly Chin, Y L Fong, et al.. (2024). Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER‐MRI studies. Pulmonary Circulation. 14(2). e12386–e12386. 2 indexed citations

Gupta, Varsha, Emmanuel Jammeh, Naomi Meardon, et al.. (2023). Unsupervised machine learning to investigate trajectory patterns of COVID-19 symptoms and physical activity measured via the MyHeart Counts App and smart devices. npj Digital Medicine. 6(1). 239–239. 4 indexed citations

Shahin, Yousef, Faisal Alandejani, Krit Dwivedi, et al.. (2022). Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. ERJ Open Research. 8(2). 503–2021. 19 indexed citations

Bellantuono, Ilaria, Rafael de Cabo, Dan Ehninger, et al.. (2020). A toolbox for the longitudinal assessment of healthspan in aging mice. Nature Protocols. 15(2). 540–574. 88 indexed citations

10.

Swift, Andrew J., Haiping Lu, Johanna Uthoff, et al.. (2020). A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis. European Heart Journal - Cardiovascular Imaging. 22(2). 236–245. 56 indexed citations

11.

Sweatt, Andrew J., Haley Hedlin, Vidhya Balasubramanian, et al.. (2019). Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Circulation Research. 124(6). 904–919. 126 indexed citations

12.

Mamazhakypov, Argen, Gayathri Viswanathan, Allan Lawrie, Ralph T. Schermuly, & Sudarshan Rajagopal. (2019). The role of chemokines and chemokine receptors in pulmonary arterial hypertension. British Journal of Pharmacology. 178(1). 72–89. 45 indexed citations

13.

Zhang, Hongda, Liting Wang, Alexander Rothman, et al.. (2017). Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 196(11). 1478–1481. 1 indexed citations

14.

Renshall, Lewis, Nadine Arnold, Laura West, et al.. (2017). Selective improvement of pulmonary arterial hypertension with a dual ET_A/ET_Breceptors antagonist in the apolipoprotein E^−/−model of PAH and atherosclerosis. Pulmonary Circulation. 8(1). 1–11. 9 indexed citations

15.

Swift, Andrew J., David Capener, Christopher Johns, et al.. (2017). Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 196(2). 228–239. 109 indexed citations

16.

Pickworth, Josephine, Alexander Rothman, James Iremonger, et al.. (2017). Differential IL‐1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. Pulmonary Circulation. 7(4). 768–776. 20 indexed citations

17.

Rhodes, Christopher J., John Wharton, Reinier A. Boon, et al.. (2012). Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 187(3). 294–302. 134 indexed citations

18.

Hurdman, Judith, Robin Condliffe, Charlie Elliot, et al.. (2011). ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. European Respiratory Journal. 39(4). 945–955. 309 indexed citations

19.

Watt, Victoria, Elaine Soon, Jay Suntharalingam, et al.. (2009). Abstract 3469: OPG:TRAIL Ratio as a Potential Biomarker for Pulmonary Arterial Hypertension. Circulation. 120. 1 indexed citations

20.

Spiekerkoetter, Edda, Christophe Guignabert, Vinicio de Jesús Pérez, et al.. (2009). S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho–Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. Circulation Research. 105(7). 639–647. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact